performed about as well in a new single-arm trial as was seen earlier with CD34+ stem cell transplant. Three-quarters of the study's 20 patients survived 5 years without relapse or recurrence ...

Kocher et al showed a significant increase in revascularization of post-infarction myocardial tissue after the intravenous administration of CD34+ human stem cells. The neoangiogenesis resulted in ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

EXG-34217 is described as a dose of autologous CD34+ haematopoietic stem cells containing a protein responsible for the ...

A research team has, for the first time in the world, revealed the identity and differentiation process of human cervical ...

Lentiviral vector (LV)–based gene therapy using CD34+ hematopoietic stem cells (HSCs) demonstrated stable factor VIII expression in severe hemophilia A patients, with higher vector copy numbers ...

CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, named its new Board of Directors led by co-founder Jérôme Koch, in line with recent bridge financing organized ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing ...

Their findings led to a novel approach for engineered Notch ligand-induced expansion of stem cell numbers from umbilical cord blood exposure. This method produced a substantial increase in the number ...